The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Open accessAbstract
Background: Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods: Open‐label, nonrandomized, multicenter, phase 3 study to validate the 18 F‐labeled β‐amyloid tracer florbetaben by comparing in vivo PET imaging with post‐mortem histopathology. Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty‐six of 47 neuritic β‐amyloid‐positive cases were read as PET positive, and 24 of 27 neuritic β‐amyloid plaque‐negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue‐scan matched analysis was performed. In areas known to strongly accumulate β‐amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively. Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology‐confirmed neuritic β‐amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD. Trial registration: ClinicalTrials.gov NCT01020838 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Positron emission tomography (PET) ligands have been shown to provide a minimally invasive estimate of the neuropathological features of AD, such as Aβ neuritic plaque deposition.15,16,17,18”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [18]
In the citing paper
“These and other studies 13,24,133,134 strongly support the concept of AD as being an amyloid-provoked, or facilitated, tauopathy, although there is also evidence that both pathologies act in synergy 135 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [135]
In the citing paper
“For example, large autopsy studies have demonstrated a high sensitivity and specificity for amyloid PET to distinguish individuals with subsequent autopsy findings of no or sparse neuritic plaque from individuals with moderate to frequent plaque.16,17,18”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“Middle frontal gyrus Intense [19] 18/21 (85.”
InfluentialStatistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 9,034
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citationConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Scheltens, P., Leys, D., Barkhof, F., Huglo, D. G., Weinstein, H. C., Vermersch, P., Kuiper, M. A., Steinling, M., Wolters, E. C., & Valk, J. (1992) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.10.967 · Cited by 1,811
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“Consistent with previous studies, only 44 of 57 (77%) patients with a clinical diagnosis of AD in the present study were actually found to have brain b-amyloid [21].”
ResultSelf-citationPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Self-citationPET of Brain Amyloid and Tau in Mild Cognitive Impairment
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054625 · Cited by 731
A Simple Method for the Analysis of Clustered Binary Data
Rao, J. N. K., & Scott, A. J. (1992) · Biometrics · doi:10.2307/2532311 · Cited by 696
Rowe, C. C., Ackerman, U., Browne, W. F., Mulligan, R. S., Pike, K. E., O'Keefe, G. J., Tochon‐Danguy, H., Chan, G., Berlangieri, S. U., Jones, G. R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 680
Self-citationBarthel, H., Gertz, H., Dresel, S. H. J., Peters, O., Bartenstein, P., Büerger, K., Hiemeyer, F. J., Wittemer‐Rump, S., Seibyl, J. P., Reininger, C. B., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 600
Self-citationThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias
Villemagne, V. L., Ong, K. T., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G. R., O'Keefe, G. J., Ackerman, U., Tochon‐Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 378
Self-citationNelissen, N., Laere, K. V., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M. J. B., Bormans, G. M., Brooks, D. J., & Vandenberghe, R. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 335
Yamamoto, T., & Hirano, A. (1986) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1986.tb00677.x · Cited by 320
Clinical Validation of 18 F-AZD4694, an Amyloid-β–Specific PET Radioligand
Cselényi, Z., Eriksdotter, M., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnström, P., Varnäs, K., Svensson, S., & Farde, L. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094029 · Cited by 225
Stankoff, B., Freeman, L. A., Aigrot, M., Chardain, A., Dollé, F., Williams, A., Galanaud, D., Armand, L., Lehéricy, S., Lubetzki, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22320 · Cited by 214
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease
Villemagne, V. L., Mulligan, R. S., Pejoska, S., Ong, K. T., Jones, G. R., O'Keefe, G. J., Chan, J. G., Young, K., Tochon‐Danguy, H., Masters, C. L., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2088-x · Cited by 197
Self-citationThal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains
Becker, G., Ichise, M., Barthel, H., Luthardt, J., Patt, M., Seese, A., Schultze‐Mosgau, M., Rohde, B., Gertz, H., Reininger, C. B., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107185 · Cited by 122
Self-citationBarthel, H., Luthardt, J., Becker, G., Patt, M., Hammerstein, E., Hartwig, K., Eggers, B., Sattler, B., Schildan, A., Hesse, S., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1821-1 · Cited by 101
Self-citationAmyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99 · cited 1×
“Progress in research to improve diagnostic accuracy and treatment for Alzheimer disease (AD) depends on the characterization of underlying pathophysiologic mechanisms [1].”
BackgroundSchipke, C. G., Peters, O., Heuser, I., Grimmer, T., Sabbagh, M. N., Sabri, O., Hock, C., Kunz, M., Kuhlmann, J., Reininger, C. B., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000339367 · Cited by 63
Self-citationIn vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer
Fodero‐Tavoletti, M. T., Brockschnieder, D., Villemagne, V. L., Martin, L., Connor, A. R., Thiele, A., Berndt, M., McLean, C., Krause, S., Rowe, C. C., et al. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.03.001 · Cited by 61
Self-citationSabbagh, M. N. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.535 · Cited by 52
Self-citationWong, D. F., Moghekar, A., Rigamonti, D., Brašić, J. R., ROUSSET, O. G., Willis, W. D., Buckley, C. J., Smith, A. P. L., Gok, B., Sherwin, P. F., et al. (2012) · Molecular Imaging and Biology · doi:10.1007/s11307-012-0583-x · Cited by 45
Cited by
Sorted by citations
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Metadata
- Authors
- Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., Beach, T. G., Rowe, C. C., Leverenz, J. B., Ghetti, B., Ironside, J. W., Catafau, A. M., Stephens, A. W., Mueller, A., Koglin, N., Hoffmann, A., Roth, K., Reininger, C., Schulz‐Schaeffer, W. J., & Florbetaben Phase 3 Study Group
- Affiliations
- University Hospital Leipzig (DE)
- Banner Sun Health Research Institute (US)
- Molecular Neuroimaging LLC New Haven CT USA
- Nagoya City University (JP)
- Hamamatsu University (JP)
- Koseikai Hospital Toyohashi Japan
- Tokyo Metropolitan Institute of Gerontology (JP)
- Institute of Brain and Blood Vessels (JP)
- The University of Melbourne (AU)
- University of Washington (US)
- Indiana University Indianapolis (US)
- University of Edinburgh (GB)
- Piramal (Germany) (DE)
- Piramal Imaging GmbH Berlin Germany
- Bayer (Germany) (DE)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Sabri, Osama
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2015-03-27
- Volume
- 11
- Issue
- 8
- Pages
- 964-974
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2169508236
- Cited by
- 602
- References
- 33
- Citations by year
- 2026: 57 · 2025: 64 · 2024: 59 · 2023: 50 · 2022: 56 · 2021: 64 · 2020: 61 · 2019: 46 · 2018: 42 · 2017: 47 · 2016: 42 · 2015: 13
- FWCI
- 39.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Bioscript Medical
- Piramal Imaging S.A
- Bayer Pharma AG
- Piramal Imaging S.A.
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- florbetaben, amyloid PET
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Aniline Compounds, Brain, Diagnosis, Female, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Middle Aged, Psychiatric Status Rating Scales, Radiography, ROC Curve, Stilbenes, Cohort Studies, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
